<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433979</url>
  </required_header>
  <id_info>
    <org_study_id>HHP-79215</org_study_id>
    <nct_id>NCT00433979</nct_id>
  </id_info>
  <brief_title>Study of Pharmacokinetics in HIV-infected Women</brief_title>
  <official_title>Predictors of Antiretroviral Pharmacokinetics in HIV-infected Women With Virologic Suppression on Combination Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Women's College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Women's College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women represent an increasing proportion of HIV cases globally and in Canada, yet are
      underrepresented in clinic trials. It is therefore critical to conduct this study on
      antiretroviral (ARV) pharmacokinetics (PK) in women to obtain additional information on ARV
      drug levels in women and their relation to adverse events (AEs).

      The hypothesis for this study is three-fold:

        1. that the mean drug levels (Cmin and Cmax) of ARVs will be significantly higher in our
           female population as compared to the mean drug levels in the historical HIV population
           (which is primarily men)

        2. that ARV drug levels, particularly Cmin, are associated with body weight in women

        3. that higher ARV drug levels, particularly Cmax, are associated with higher frequency and
           severity of AEs.

      The objectives of this study are as follows:

      Primary objectives:

        1. To demonstrate that levels of Protease Inhibitors (PIs) and Non-Nucleoside Reverse
           Transcriptase Inhibitors (NNRTIs) are significantly higher in our female population as
           compared to the mean drug levels in the historical general population (which is
           primarily men).

        2. To determine the association between PI and NNRTI minimum concentration (Cmin) and body
           weight in our female population.

      Secondary objectives

        1. To determine the association between maximum concentration (Cmax) and the frequency and
           severity of AEs as measured by the proportion of patients with grade 2 or higher
           laboratory or clinical AEs and the Symptom Index Score in women.

        2. To determine the association between ARV drug levels and age, race, height, body mass
           index, adherence, hormonal levels and therapy, menstruation history, duration of HIV
           infection, duration on ARV therapy, baseline viral load, baseline CD4 count, present CD4
           count, hepatitis B or C infection, class of ARVs, presence of ritonavir and other
           medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Predictors of antiretroviral pharmacokinetics in HIV-infected women with virologic
      suppression on combination antiretroviral therapy

      Background

      Women in Canada constitute the fastest growing population groups at risk for infection with
      HIV and AIDS. Women now represent approximately 40% of all AIDS cases worldwide and
      approximately 20% of cases in Canada. Although the AIDS epidemic has been ongoing for more
      than 20 years, surprisingly little is known about the differential efficacy and toxicity of
      various antiretroviral (ARV) drugs in women as compared to men. This gap in knowledge is a
      result of the initial exclusion of and continued underrepresentation of women in ARV clinical
      trials. Many studies suggest that HIV-infected women taking ARV treatment (ART) have more
      adverse events (AEs) than men, especially in relationship to systemic symptoms like diarrhea,
      as well as organ toxicity, including hepatotoxicity, lactic acidosis, peripheral neuropathy
      and, notably, lipodystrophy. Currently, the occurrence and management of AEs is the most
      important issue in the treatment of HIV. Understanding the reasons for the differences of AEs
      in HIV-infected women is critical and has yet to be evaluated within a large cohort. It is
      unknown whether these differences relate to hormonal influences, drug metabolism, adherence,
      fat distribution, body size or other factors. Some small studies have found that drug levels
      (e.g. Cmin, Cmax, AUC) are higher in women and are associated with increased toxicity.
      Ultimately, we plan to conduct a randomized clinical trial (RCT) to assess the utility of
      therapeutic drug monitoring (TDM) and ARV drug dose adjustment on the frequency of AEs in
      women. Prior to conducting this RCT, it is critical to conduct this study on ARV
      pharmacokinetics (PK) in women to obtain additional information on ARV drug levels in women
      and their relation to AEs.

      Hypothesis

      The hypothesis for this study is three-fold:

        1. that the mean drug levels (Cmin and Cmax) of ARVs will be significantly higher in our
           female population as compared to the mean drug levels in the historical HIV population
           (which is primarily men)

        2. that ARV drug levels, particularly Cmin, are associated with body weight in women

        3. that higher ARV drug levels, particularly Cmax, are associated with higher frequency and
           severity of AEs.

      Patient population

      Eighty HIV-infected women from 8 Canadian sites who have been on their first combination ART
      regimen containing either a PI or an NNRTI (since these are the ARV agents eligible for PK
      analysis) for at least three months and who have evidence of full virologic suppression (HIV
      RNA VL less than 50 copies/mL) on at least two occasions at least one month apart.

      Objectives Primary objectives

        1. To demonstrate that the Cmin and Cmax of PIs and NNRTIs are significantly higher in our
           female population as compared to the mean drug levels in the historical general
           population (which is primarily men).

        2. To determine the association between PI and NNRTI Cmin and body weight in our female
           population.

      Secondary objectives

        1. To determine the association between Cmax and the frequency and severity of AEs as
           measured by the proportion of patients with grade 2 or higher laboratory or clinical AEs
           and the Symptom index score in women.

        2. To determine the association between ARV drug levels and age, race, height, body mass
           index, adherence, hormonal levels and therapy, menstruation history, duration of HIV
           infection, duration on ARV therapy, baseline VL, baseline CD4 count, present CD4 count,
           hepatitis B or C infection, class of ARVs, presence of ritonavir and other medications.

      Study design

      The study will be a cross-sectional study with ARV drug levels (Cmin and Cmax) measured
      weekly for three weeks Three samples will be taken from each subject to reduce variability
      due to both technologic and biologic sources. Data will be collected on demographic
      characteristics, clinical disease and ARV history and on clinical toxicities at the first
      visit. Blood work will be carried out on the first visit to assess for laboratory toxicity
      and hormonal levels.

      Data analysis

      Drug levels will be summarized with the mean of the 3 values for Cmin and Cmax for each woman
      for their PI or NNRTI and compared to the mean values of the general HIV population. Cmin and
      Cmax will be classified into high and low levels with a high level defined as less than or
      equal to 1.5 X arithmetic population mean for each drug. Characteristics of patients with
      high drug levels will be compared to those of patients with low drug levels. Univariate and
      multivariate logistic regression models will be used to identify independent associations of
      patient characteristics with high drug levels. The proportions of patients with AEs and the
      median number of AEs per patient will be compared between patients with high Cmax and
      patients with low Cmax.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">88</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antiretroviral treatment</intervention_name>
    <description>These antiretroviral drugs are a part of the participant's current drug regimen.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be drawn before and after antiretroviral drugs are taken for visits 1-3.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patient population will consist of 80 HIV-infected women (who are on their first cART
        regimen containing either a PI or an NNRTI for at least three months and who have evidence
        of full virologic suppression (HIV RNA VL &lt; 50 copies/mL) on at least two occasions at
        least one month apart. The first cART regimen can include ARV switches as long as these
        switches are not due to virologic failure. The patient population is being limited to women
        who have full virologic suppression to avoid inclusion of women with difficulty with drug
        adherence.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be HIV infected

          -  Patient must be 18 years old or older

          -  Patient must be a biologic woman

          -  Patient must be taking her first combination ARV regimen that includes a PI or an
             NNRTI for the past three months with no changes in any agent of the combination in
             that period (first combination ARV regimen is defined as a regimen started when the
             patient was ARV-na√Øve; however switches are allowed as long as the switches are not
             for virologic failure)

          -  Patient must be taking either a PI or an NNRTI but not both

          -  If taking a PI, patient must be taking only one PI excluding low dose ritonavir used
             as boosting

          -  Patient must have a viral load &lt; 50 copies/mL on two occasions at least 1 month apart
             including a value within three months before the baseline visit

          -  Patient has to have signed and dated a full informed consent

        Exclusion Criteria:

          -  Patient who would have difficulty participating in a trial due to non-adherence or
             substance abuse

          -  Patient who is pregnant or breast-feeding

          -  Patient with a malignancy receiving systemic chemotherapy

          -  Patient with end stage organ disease

          -  Patient with other significant non-HIV underlying disease that might impinge upon
             disease progression or death

          -  Patient who is not taking standard dosing of a PI or NNRTI as listed in Appendix G
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona R Loutfy, MD FRCPC MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women's College Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children and Women's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown Infectious Diseases Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital District Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences - McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Health Services</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1N 6N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canadian Immunodeficiency Research Collaborative</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network - Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Hospital HIV Care Program</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de recherche du Centre hospitalier de l'Universite de Montreal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Chest Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chuq/Chul</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dr. Mona Loutfy</name_title>
    <organization>Women's College Research Institute</organization>
  </responsible_party>
  <keyword>Anti-HIV agents</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>ARV-associated Adverse Events</keyword>
  <keyword>HAART</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Protease Inhibitors</keyword>
  <keyword>Non-nucleoside Reverse Transcriptase Inhibitors</keyword>
  <keyword>Women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

